[1] CHEN W,ZHENG R,ZENG H,et al. Annal report on status of cancer in China[J]. Chin J cancer Res,2015,27(1):2-12. [2] 杨彦辉,邓波,王如文,等.应用ROC曲线评价PET/CT联合肿瘤标志物对肺癌的诊断效能[J]. 肿瘤学杂志,2016,22(2):110-115. [3] 段国辰,郭涛.非小细胞肺癌EGFR基因突变的研究进展[J]. 河北医药,2015,37(23): 3637-3639. [4] 王冠军,赫捷.肿瘤学概论[M]. 1版.北京:人民卫生出版社,2013:200-207. [5] 周春燕,冯作化,药立波,等.医学分子生物学[M]. 2版.北京:人民卫生出版社,2014:232-234. [6] 张静,梁智勇,曾喧,等.应用蝎形探针扩增阻滞突变系统检测非小细胞肺癌表皮生长因子受体基因突变与病理改变的关系[J]. 中华病理学杂志,2008,37(5):294-299. [7] 赵静,赵金银,赵肖,等.ARMS技术联合Taqman 探针检测100例非小细胞肺癌EGFR基因突变[J]. 中国肺癌杂志,2013,16(1):25-32. [8] 邱田,凌云,山灵,等.非小细胞肺癌患者表皮生长因子受体Kras基因突变检测及与临床病理特征的相关性[J]. 中国肿瘤临床与康复,2015,22(6):678-680. [9] 郑军,谢贵元,李姣,等.非小细胞肺癌EGFR基因突变的临床意义研究[J]. 中国肿瘤临床,2014,41(14):904-907. [10] SHAMA S V,BELL D W,SELTLEMAN J,et al. Epidermal growth factor receptor mutations in lung cancer[J]. Nat Rev Cancer,2007,7(3):69-81. [11] TENRESSEN J A,BIGHAM A W, O' CONNOR T D,et al. Evolution and functional impact of rare coding Variation from deep sequencing of human exons[J]. Science,2012,337(6090):64-69. [12] YASUDA H,KOBAYSHI S,COSTA D B,et al. EGFR exon 20 insertion mutations in non-small-cell lung Cancer Preclinical data and clinical caplications[J]. Lancer Oncol,2012,13(1):e 23-31. [13] PAN H,LIU R,LI S. Effects of lootinib on advanced non-small cell lung cancer with different EGFR phenotypes[J]. Cell Biochem Biophys,2014,70(1):553-558. [14] 颜瑾,周琪卉,宁雅静,等.53例CT引导下经皮肺穿剌活检临床分析[J]. 临床肺科杂志,2016,21(10):1814-1816. [15] 郑名华,孙国栋,张郧樊,等.肿瘤标志物在肺癌诊疗中的研究进展[J]. 中国医学创新,2016,13(4):145-148. |